Drug Discovery

Xencor, MD Anderson enter collaboration to develop novel T cell-engaging bispecific antibodies for potential treatment of cancer

Xencor and The University of Texas MD Anderson Cancer Center announced a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.

Fujifilm to invest $2bn to build large-scale cell culture manufacturing site in US

Fujifilm is set to invest about $2bn to build a new large-scale cell culture production site for biopharmaceuticals in the US.

Angelini Pharma to buy Arvelle Therapeutics for up to $960m

Angelini Pharma has agreed to acquire Swiss biopharmaceutical company Arvelle Therapeutics in a deal valued up to $960m.

India gives restricted emergency use approval for two Covid-19 vaccines

India's Central Drugs Standard Control Organisation (CDSCO) has given the restricted emergency use approval for Covid-19 vaccines of Serum Institute of India and Bharat Biotech.

Moderna in talks with South Korea to supply 40 million doses of Covid-19 vaccine

Biotechnology company Moderna is negotiating with the South Korean government to potentially provide 40 million or more doses of its vaccine against Covid-19.

Aurobindo, COVAXX sign deal to develop Covid-19 vaccine UB-612

Aurobindo Pharma has signed an exclusive license agreement with US-based COVAXX to develop the latter’s UB-612 multitope peptide-based vaccine to fight Covid-19.

Hyundai Bioscience develops injection drug for potential treatment of severe cases of Covid-19

Hyundai Bioscience announced that CNPharm, its major shareholding bio tech company, has succeeded in developing 'Poly-COV01,' an injection drug for the potential treatment of patients with severe cases of Covid-19.

Servier to buy Agios’ oncology business for up to $2bn

Pharmaceutical company Servier has agreed to acquire oncology business from Agios Pharmaceuticals for up to $2bn.

Neurogene closes $115m series B financing

Neurogene, a company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the completion of a $115m Series B financing.